以创新驱动发展 抢滩再生医学赛道

Core Viewpoint - The company, He Yuan Bio, has established itself as a leader in the cell and gene therapy (CGT) industry by leveraging strong technological capabilities and strategic focus, aiming to expand its market presence and competitiveness in regenerative medicine [1][2][4]. Group 1: Company Overview - He Yuan Bio was founded in 2013 and specializes in providing integrated CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services for cell and gene therapy research and drug development [2]. - The company has developed two core technology clusters: carrier development technology and production process and quality control technology for cell and gene therapy [1][2]. Group 2: Technological Innovation - The company has made significant investments in R&D, with R&D expenses reaching 34.66 million yuan, accounting for 19.22% of its operating revenue in the first three quarters of 2025 [3]. - He Yuan Bio has established a comprehensive technology platform for cell and gene therapy, including molecular biology, virus packaging, and cell function research platforms, achieving leading international levels in viral vector technology [2][3]. Group 3: Market Position and Growth - The company has collaborated with over 14,700 research laboratories and has supported more than 600 CDMO projects, including 5 Phase III clinical projects, and assisted clients in obtaining 60 clinical trial approvals, including 14 from the FDA [3][4]. - The company’s production capacity is among the top in the international industry, with its Lingang industrial base featuring 11 GMP carrier production lines and 18 GMP cell production lines [4][5]. Group 4: Future Development and Strategy - He Yuan Bio plans to expand into the regenerative medicine sector by establishing a wholly-owned subsidiary, He Yuan He Mei, to address industry challenges related to cell safety and traceability [5][6]. - The company is actively exploring international markets and has initiated collaborations with domestic biotech firms to support their overseas clinical trial applications and facilitate technology licensing [6][7].